Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Operating Income of -$86.82 million for fiscal year 2025.
INOVIO PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$86.82M | +22.8% |
| 2024 | -$112.40M | +21.9% |
| 2023 | -$143.94M | +46.2% |
| 2022 | -$267.57M | +11.2% |
| 2021 | -$301.22M | -142.8% |
| 2020 | -$124.08M | -11.7% |
| 2019 | -$111.11M | -18.1% |
| 2018 | -$94.09M | -12.5% |
| 2017 | -$83.64M | -9.7% |
| 2016 | -$76.24M | -122.4% |
| 2015 | -$34.28M | +13.2% |
| 2014 | -$39.50M | -102.1% |
| 2013 | -$19.54M | +16.8% |
| 2012 | -$23.49M | -8.6% |
| 2011 | -$21.64M | -12.6% |
| 2010 | -$19.22M | -37.7% |
| 2009 | -$13.96M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$21.21M | +22.4% | +8.1% |
| June 30, 2025 | -$23.08M | +30.5% | +7.8% |
| March 31, 2025 | -$25.05M | +20.4% | +8.4% |
| September 30, 2024 | -$27.35M | +23.1% | +17.6% |
| June 30, 2024 | -$33.20M | +10.4% | -5.4% |
| March 31, 2024 | -$31.48M | +28.4% | +11.4% |
| September 30, 2023 | -$35.55M | +0.6% | +4.0% |
| June 30, 2023 | -$37.04M | +64.4% | +15.7% |
- INOVIO PHARMACEUTICALS, INC. showed an increase of +22.8% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, INOVIO PHARMACEUTICALS, INC.’s operating income has declined by 522.0% (from -$13.96 million to -$86.82 million).
- The most recent figure is from INOVIO PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: